Federated Hermes Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR

Federated Hermes Inc. acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 558,700 shares of the company’s stock, valued at approximately $31,622,000.

Several other institutional investors have also added to or reduced their stakes in KYMR. Campbell & CO Investment Adviser LLC acquired a new position in Kymera Therapeutics in the 3rd quarter worth $259,000. KLP Kapitalforvaltning AS lifted its holdings in shares of Kymera Therapeutics by 16.9% in the third quarter. KLP Kapitalforvaltning AS now owns 9,000 shares of the company’s stock valued at $509,000 after purchasing an additional 1,300 shares in the last quarter. Altfest L J & Co. Inc. acquired a new position in shares of Kymera Therapeutics during the third quarter worth about $301,000. Voya Investment Management LLC grew its holdings in shares of Kymera Therapeutics by 22.4% during the third quarter. Voya Investment Management LLC now owns 36,455 shares of the company’s stock worth $2,063,000 after buying an additional 6,669 shares in the last quarter. Finally, Osaic Holdings Inc. grew its holdings in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after buying an additional 1,083 shares in the last quarter.

Kymera Therapeutics Trading Down 1.7%

Shares of KYMR opened at $72.69 on Friday. The company’s fifty day simple moving average is $75.62 and its 200 day simple moving average is $59.72. Kymera Therapeutics, Inc. has a 1-year low of $19.44 and a 1-year high of $103.00. The company has a market cap of $5.23 billion, a price-to-earnings ratio of -20.25 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million during the quarter, compared to the consensus estimate of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. As a group, research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $78.06, for a total value of $2,341,800.00. Following the completion of the sale, the chief executive officer directly owned 663,077 shares of the company’s stock, valued at $51,759,790.62. This trade represents a 4.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $89.76, for a total value of $448,800.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 420,895 shares of company stock worth $37,778,351 in the last three months. Insiders own 16.01% of the company’s stock.

Analysts Set New Price Targets

KYMR has been the topic of several research reports. Stephens boosted their target price on Kymera Therapeutics from $65.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, December 11th. Barclays boosted their price objective on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research report on Tuesday. Morgan Stanley raised their target price on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. Piper Sandler reiterated an “overweight” rating and issued a $125.00 price target (up from $98.00) on shares of Kymera Therapeutics in a research note on Tuesday, December 9th. Finally, Leerink Partners increased their price objective on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $117.00.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.